Major findings supporting the involvement of CB2R in anxiety disorders
|Genetic studies||Genetic manipulation||Animal specie||Experimental test||Behavioral changes||References|
|CB2xP||Mouse, ICR||LDB||↓ vulnerability(↓ time in the lighted box and open arms)|||
|CB2–/–||Mouse, ICR||LDB||↑ vulnerability(↑ time in the lighted box and open arms)|||
|Cnr2 KO||Mouse, C57BL/6J||SD||↑ aggressive behavior|||
|Pharmacological studies||Acute treatment||Drug||Animal specie||Experimental test||Dosis||Behavioral changes||References|
|CB2R messenger RNA antisense probe||Mouse, DBA/2, C57BL/6J, BALB/c||EPM||4 µg/µL per 12 h (3 days)||↓ anxiogenic response|||
|JWH015 (CB2R agonist)||Mouse, DBA/2, C57BL/6J, BALB/c||EPM||1–20 mg/kg||↑ anxiogenic response|||
|JWH133 (CB2R agonist)||Mouse, ICR||LDB, EPM||0.5, 1, 2 mg/kg||No effect|||
|Mouse, C57BL/6J||SD||1, 2 mg/kg||↓ aggressive behavior|||
|GW405833 (CB2R agonist)||Mouse, C57BL/6J||MB||10, 30, 100 mg/kg||↓ anxiogenic response|||
|Rat, Sprague-Dawley||Rotarod||100 mg/kg|
|AM630 (CB2R antagonist)||Mouse, ICR||LDB||1, 2, 3 mg/kg||↑ anxiogenic response|||
|Chronic treatment||Drug||Animal specie||Experimental test||Dosis||Behavioral changes||References|
|AM630 (CB2R antagonist)||Mouse, ICR||LDB EPM||1, 2, 3 mg/kg per 12 h (7 days)||↓ anxiogenic response|||
|JWH133 (CB2R agonist)||Mouse, ICR||LDBEPM||0.5, 1, 2 mg/kg per 12 h (7 days)||↑ anxiogenic response|||
|rs2070956 polymorphism||Caucasian (infant)||↓ response to the treatment|||
Cnr2 KO: mouse lacking CB2R gene in the CNS with C57BL/6J background; LDB: light-dark box test; EPM: elevated plus-maze test; SD: experimental paradigm of social defeat; MB: marble-burying behavioral test. ↑: increases; ↓: decreases
We thank all participants in this study. We greatly appreciated Biorender for helping to create figure 1.
MSGG and JM conceived the presented idea. MSGG took the lead in writing the manuscript. FN and AG wrote the manuscript in consultation with MSGG. All authors provided critical feedback and helped shape the research, analysis, and manuscript.
The authors declare no conflict of interest.
© The Author(s) 2021.